HIBIO Industry Innovation Forum and Danaher Day Beijing Successfully Held, Fostering a New Ecosystem for Biopharmaceutical Industry

ShanghaiJanuary 6, 2023/PR Newswire/ -- On January 4, 2023, the "Diverse Innovation, Brilliant China -- HIBIO Industry Innovation Forum and Danaher Day," guided by the Beijing Zhongguancun Life Science Park Management Committee, jointly organized by Chang Development and Danaher China, and supported by the magazine "China Food and Drug Administration," was successfully held in Beijing. Attending the event were Yang Renquan, member of the Standing Committee of the Changping District Committee of Beijing and executive district mayor; Song Lei, director of the Pharmaceutical and Chemical Department of the Investment Promotion Bureau of the Ministry of Commerce; Zhou Yong, director of the Recombinant Drug Laboratory at the National Institutes for Food and Drug Control; Zhao Yanyi, general manager of the "China Food and Drug Administration" magazine; Wang Ying, general manager of Chang Development and chairman of Life Park Company; Li Lei, president of Danaher China's Life Sciences Platform; Wei Chunyan, vice president of government affairs at Danaher China; Yu Lihua, general manager of Cytiva China; among other distinguished guests.

This conference featured keynote speeches and roundtable dialogues, where distinguished representatives from the fields of government, industry, academia, research, medicine, and finance exchanged insights and jointly explored the new ecosystem of bioeconomic development.

Yang Renquan, Standing Committee Member of the Changping District Committee and Executive Deputy District Chief of Changping District, Beijing, stated in his speech, "As the key entrepreneurial and innovative industrial belt and the main base for high-end and sophisticated industries in Beijing, Changping District has grown into a hub for innovation resources in China's life sciences sector and an innovation engine for Beijing's pharmaceuticals and healthcare industry. The first phase of Danaher Day being held in Changping represents a collaborative exploration and ecosystem co-creation between Changping and Danaher. We hope Danaher will leverage its multi-platform advantages to expand its business footprint, partner with more enterprises to develop in Changping, and work together with us to build a modern pharmaceuticals and healthcare industry framework, creating a growth pole for high-quality economic development."

Regarding how the government and enterprises can collaborate to promote CGT technology innovation and high-quality development, Song Lei, Director of the Pharmaceutical and Chemical Industry Department of the Investment Promotion Bureau of the Ministry of Commerce, Lin Xin, Professor at Tsinghua University School of Medicine, Chair of the Department of Basic Medicine, National Distinguished Expert, and Changjiang Scholar Chair Professor, Shi Yi, Researcher at the Institute of Microbiology, Chinese Academy of Sciences, and Tian Yu, Deputy Director of the Life Science Park Service Office of Beijing Future Science City Management Committee, engaged in an in-depth discussion during the roundtable dialogue session.

Wei Chunyan, Vice President of Government Affairs at Danaher China, stated that 2023 will bring new opportunities for the global cell and gene therapy sector. As one of the largest markets, China's strategic significance is self-evident. Danaher will continue to invest in the high-quality development wave of the bioeconomy, focusing on life sciences and biotechnology as key directions. Collaborating with diverse industry forces, we will accelerate progress with like-minded individuals, making a brilliant impact in China!

From Technology Development to CommercializationCGT Full Life Cycle Management

Guided by the "14th Five-Year Plan," the scientific planning and systematic advancement of China's bioeconomy development is an important direction for aligning with the accelerating global biotechnology evolution trend and achieving high-level technological self-reliance and strength. The layout and growth of the bioeconomy contribute to promoting high-quality economic development and are essential for meeting the rapidly increasing demand for life and health. Danaher focuses on deploying in the gene therapy and cell therapy fields, providing cutting-edge life science technologies and tools, accelerating solutions from technology development to commercial transformation, and collaborating with industry partners to jointly explore new pathways for disease treatment.

During the second round of the roundtable dialogue at the conference, Zhang Yi, Chief Scientist of the National Public Cord Blood Hematopoietic Stem Cell Bank, Dr. Yang Huan, former Clinical Medicine Researcher at the Center for Drug Evaluation of the National Medical Products Administration, Gao Lu, CEO of Yuan Bio, and Li Lei, President of Danaher China's Life Science Platform, engaged in an in-depth discussion on the full lifecycle management of CGT from technology development to commercialization.

Li Lei, President of Danaher Life Sciences Platform, stated: With the rapid development of gene and cell therapy, Danaher has long been committed to providing comprehensive life science solutions to scientists, entrepreneurs, and regulatory agencies across various fields. In early 2022, we launched the "Creating and Elevating China" Localization 4.0 Strategy, integrating local innovation, local manufacturing, and local commercialization capabilities to promote our business operations in China. Going forward, we will continue to leverage our global technological advantages and collaborate with partners from all sectors to drive the rapid growth of China’s biotechnology and healthcare industries.

Diverse Collaborative InnovationCGT Industry Ecosystem

Currently, life sciences have become an active field in cutting-edge scientific research. Within Changping District, the Zhongguan Village Life Science Park has been established, focusing on life science research, biotechnology, and innovation in the biomedical field. As the operation service provider of the industrial park, Beijing Changping Science Park Development Co., Ltd. (Chang Development) centers on asset operation services and industry promotion services to build a high-end industrial cluster and a series of scientific and technological innovation service platforms.

In the final roundtable session of the conference, Lv Bing, Executive Director of the medical investment division of Beijing Changping Science Park Development Co., Ltd., Zhao Xueqiang, co-founder of Huaxia Yingtai, Zhang Yan, co-founder of Megarobo Technology, and Yu Lihua, General Manager of Cytiva China, shared professional insights on how to achieve diversified collaborative innovation and jointly build a CGT industry ecosystem.

Yu Lihua, General Manager of Cytiva China, stated: As a global emerging therapeutic field, CGT is flourishing within China's biopharmaceutical ecosystem. As a pioneer in the global life sciences sector under Danaher, Cytiva boasts strong product lines and innovative solution capabilities. Among these, the end-to-end solutions for cell and gene therapy have gained extensive customer support and validation. Moving forward, Cytiva will continue to focus on helping customers enhance the speed and efficiency of research and production processes, driving the development of the CGT industry alongside partners, and jointly building the CGT ecosystem.